RUNX1T1 and acute myeloid leukemia: At present, the AML subtypes most likely to benefit from these endeavors are those harboring DDR pathway deficits as a consequence of RUNX1-RUNX1T1 or PML-RARα fusions as well as FLT3 or IDH1 mutations.